CoChat

Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain

Nemeroff, Charles B. · 2003 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pharmacotherapeutic management of bipolar disorder has advanced considerably since the introduction of lithium therapy nearly 50 years ago. The sizable percentage of patients who do not respond adequately to lithium and/or are intolerant to its side effects has served as an impetus for identifying alternative pharmacotherapeutic agents. Recent advances in the understanding of the neurotransmitter systems and their receptors as it applies to treatment of bipolar disorder has, in part, led to progress in delineating applications of anticonvulsant/antiepileptic drugs (AEDs) in this area. Although the efficacy of many drugs has been evaluated in patients with this disorder, medication tolerability and adherence issues related to unfavorable side effect profiles are substantial impediments to the development of novel pharmacotherapies. The potential for excessive weight gain as a side effect of certain psychopharmacologic agents remains a concern to both clinicians and patients. METHOD: English-language literature from 1985-2001 in MEDLINE was searched for the terms bipolar disorder, anticonvulsant, antiepileptic, lithium, antipsychotic, weight, and compliance. This article reviewed current therapeutic options for bipolar disorder, including newer AEDs and atypical antipsychotic drugs, with emphasis on the issue of weight gain and possible approaches to minimizing this risk. RESULTS: Certain newer AEDs are characterized by more favorable safety and tolerability profiles that include weight loss as a desirable side effect. Because bipolar disorder is associated with unacceptably high rates of relapse, recurrence, and morbidity, the concept of pharmacotherapeutic efficacy logically not only includes symptom relief but also necessarily encompasses issues related to regimen tolerability and adherence. CONCLUSION: There is a need for guidelines to help physicians carefully formulate and individualize management plans to reach safe, effective, and cost-efficient patient outcomes. Monitoring the weight of patients with bipolar disorder and educating them regarding this issue should be standard components of any treatment plan.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v64n0506

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Cited by

See all 88

Metadata

Authors
Nemeroff, C. B.
Affiliations
Emory University (US)
Corresponding author
Nemeroff, Charles B.
Venue
The Journal of Clinical Psychiatry
Published
2003-05-15
Volume
64
Issue
5
Pages
532-539
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2094246063
Cited by
86
References
55
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2014: 2 · 2013: 6 · 2012: 3
FWCI
8.60
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar disorder, drug safety, lithium, atypical antipsychotics, weight gain, medication adherence, tolerability, weight loss, relapse prevention
MeSH terms
Topiramate, Anticonvulsants, Bipolar Disorder, Clinical Protocols, Female, Fructose, Humans, Lithium, Obesity, Patient Compliance, Patient Education as Topic, Antipsychotic Agents, Weight Gain, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain. https://app.cochat.ai/papers/10.4088/jcp.v64n0506
The paper
Nemeroff, C. B. (2003). Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n0506

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.